ArticleACS chemical neuroscience2025
Mass Spectrometry Imaging Reveals the Distribution of a GABRG2 Targeting Antisense Oligonucleotide and Its Functional Effect in Rat Brain.
Article in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the development of antisense oligonucleotides (ASOs) has gained wide interest as therapeutic agents for their potential in treating neurodegenerative diseases. ASOs are chemically modified oligonucleotides that are designed to bind complementary regions of RNA or DNA and, thereby, modulate the expression of the corresponding protein. Here, we present a multiomics approach to investigate the spatial distribution and biological effect of an ASO designed to target the mRNA that translates for γ-aminobutyric acid A receptor γ2 subunit (GABRG2), which is abundantly expressed within the brain. In this study, a rat model was used to develop a multiomics mass spectrometry (imaging) approach to map ASO distribution in brain and kidney, followed by in-depth analysis of the lipidome, proteome, and metabolome. The ASOs' phosphorothioate-modified backbone was visualized using an optimized matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) protocol, which included the introduction of an organic washing step prior to MALDI-MSI acquisition and an optimized acquisition method. On consecutive tissue sections, reactive matrix FMP10 was applied to enable the visualization of neurotransmitters, which revealed significant alterations for multiple neurotransmitters. Lastly, on the same slide, the ASOs' effect on the lipidome and proteome of the brain was further analyzed. Proteins corresponding to synaptic activity and plasticity were mainly affected by the ASO. This spatial omics approach provides insight into the comprehensive molecular landscape of ASO-mediated interventions and their promise as treatments for neurological disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.